CCLA Investment Management’s Honeywell HON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-147,125
Closed -$29.7M 63
2024
Q3
$29.7M Hold
147,125
0.46% 58
2024
Q2
$29.7M Buy
147,125
+1,789
+1% +$340K 0.46% 58
2024
Q1
$28.1M Sell
145,336
-897
-0.6% -$169K 0.43% 59
2023
Q4
$28.4M Buy
146,233
+2,017
+1% +$364K 0.46% 58
2023
Q3
$25.1M Sell
144,216
-234
-0.2% -$42.8K 0.47% 61
2023
Q2
$28.2M Buy
144,450
+22
+0% +$4.09K 0.5% 61
2023
Q1
$26M Hold
144,428
0.51% 62
2022
Q4
$29.2M Sell
144,428
-14,132
-9% -$2.7M 0.66% 58
2022
Q3
$25M Buy
+158,560
New +$27.6M 0.6% 58
2022
Q1
$38.5M Sell
209,751
-67,182
-24% -$12.4M 0.69% 58
2021
Q4
$54.4M Sell
276,933
-18,636
-6% -$3.76M 0.89% 55
2021
Q3
$59.2M Buy
295,569
+1,261
+0.4% +$269K 0.98% 50
2021
Q2
$60.8K Sell
294,308
-270
-0.1% -$57.1K 0.74% 49
2021
Q1
$60.3M Buy
294,578
+90,622
+44% +$17.7M 1.21% 43
2020
Q4
$40.8M Buy
203,956
+273
+0.1% +$49.6K 0.92% 54
2020
Q3
$31.6M Sell
203,683
-4,486
-2% -$667K 0.86% 52
2020
Q2
$28.4M Buy
+208,169
New +$27.5M 0.89% 46

Other funds holding HON

CCLA Investment Management's HON Position: Q4 2024 in Review

CCLA Investment Management sold out of Honeywell (HON) in Q4 2024, closing a stake of 147,125 shares — an estimated $29.7M sold.

CCLA Investment Management first reported a position in HON in Q2 2020 and held it in 17 quarters. The position peaked at $60.3M in Q1 2021. 2,727 funds tracked by Wall St. Rank hold HON as of Q4 2024.

  • CCLA Investment Management reported no remaining Honeywell position as of Q4 2024 after selling out during the quarter.
  • CCLA Investment Management sold 147,125 Honeywell shares in Q4 2024, an estimated $29.7M.
  • CCLA Investment Management first reported a position in Honeywell in Q2 2020 and held it in 17 quarters.
  • CCLA Investment Management's Honeywell position peaked at $60.3M in Q1 2021.
  • 2,727 funds tracked by Wall St. Rank held Honeywell as of Q4 2024.

Based on CCLA Investment Management's 13F filing for Q4 2024, filed 14 Jan 2025.